Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Oct;6(4):620–629. doi: 10.1016/j.nurt.2009.07.003

Animal models of chemotherapy-evoked painful peripheral neuropathies

Nicolas Authier 1,2,3,✉, David Balayssac 1,4,3, Fabien Marchand 1,2, Bing Ling 1, Aude Zangarelli 4, Juliette Descoeur 5, François Coudore 6, Emmanuel Bourinet 5, Alain Eschalier 1,2,3
PMCID: PMC5084284  PMID: 19789067

Summary

This review examines recent preclinical research on toxic peripheral neuropathy and potential therapeutic developments. Chemotherapy-induced peripheral neurotoxicity is a major clinical problem because it represents the dose-limiting side effects of a significant number of antineoplastic drugs. Patients are unable to complete full or optimal treatment schedules. The incidence of chemotherapy-induced peripheral neuropathy varies depending on the drugs and schedules used, and this can be quite high, particularly when neurophysiological methods are used to make a diagnosis. However, even when chemotherapy-induced peripheral neuropathy is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. As such, improved understanding of the pathophysiology of chemotherapy-induced neurotoxicity need for animal models is clinically relevant and will assist in the development of future neuroprotective strategies and also in the design of novel chemotherapies with improved toxicity profiles. In this review, the features of animal models of chemotherapy-induced painful neuropathy developed for 20 years, due to the administration of the most widely used drugs, such as platinum drugs, taxanes, and vinca alkaloids, will be discussed. In a second part, data available on neuroprotectants and treatment strategies, evaluated using these previous animal models in the attempt to prevent neuropathic pain, will be summarized.

Key Words: Pain, anti-cancer agents, neurotoxicity, prevention, neuropathy

References

  • 1.Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst. 2008;13:27–46. doi: 10.1111/j.1529-8027.2008.00156.x. [DOI] [PubMed] [Google Scholar]
  • 2.Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63:761–767. doi: 10.1007/s00280-008-0876-6. [DOI] [PubMed] [Google Scholar]
  • 3.Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective stratégies. Curr Med Chem. 2008;15:3081–3094. doi: 10.2174/092986708786848569. [DOI] [PubMed] [Google Scholar]
  • 4.Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol. 2006;18:321–324. doi: 10.1097/01.cco.0000228735.39885.3e. [DOI] [PubMed] [Google Scholar]
  • 5.Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep. 2006;10:279–287. doi: 10.1007/s11916-006-0033-z. [DOI] [PubMed] [Google Scholar]
  • 6.Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006;72:151–169. [PubMed] [Google Scholar]
  • 7.Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr opin Neurol. 2007;20:719–725. doi: 10.1097/WCO.0b013e3282f1a06e. [DOI] [PubMed] [Google Scholar]
  • 8.Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol. 2008;6:455–467. [PubMed] [Google Scholar]
  • 9.Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996;73:259–265. doi: 10.1016/0306-4522(96)00020-6. [DOI] [PubMed] [Google Scholar]
  • 10.Weng HR, Cordelia JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain. 2003;103:131–138. doi: 10.1016/S0304-3959(02)00445-1. [DOI] [PubMed] [Google Scholar]
  • 11.Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci. 1998;18:6480–6491. doi: 10.1523/JNEUROSCI.18-16-06480.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tanner KD, Levine JD, Topp KS. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol. 1998;395:481–492. doi: 10.1002/(SICI)1096-9861(19980615)395:4<481::AID-CNE5>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 13.Tanner KD, Reichling DB, Gear RW, Paul SM, Levine JD. Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience. 2003;118:809–817. doi: 10.1016/S0306-4522(03)00023-X. [DOI] [PubMed] [Google Scholar]
  • 14.Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD. Interaction of transient receptor potential vanilloid 4, integrin, and Src tyrosine kinase in mechanical hyperalgesia. J Neurosci. 2008;28:1046–1057. doi: 10.1523/JNEUROSCI.4497-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Thibault K, Van Steewinckel J, Brisorgueil MJ, et al. Serotonin 5-HT2A receptor involvement and Fos expression at the spinal level in vincristine-induced neuropathy in the rat. Pain. 2008;140:305–322. doi: 10.1016/j.pain.2008.09.006. [DOI] [PubMed] [Google Scholar]
  • 16.Authier N, Coudore F, Eschalier A, Fialip J. Pain related behaviour during vincristine-induced neuropathy in rats. NeuroReport. 1999;10:965–968. doi: 10.1097/00001756-199904060-00013. [DOI] [PubMed] [Google Scholar]
  • 17.Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. A new animal model of vincristine-induced nociceptive peripheral neuropathy. NeuroToxicol. 2003;24:797–805. doi: 10.1016/S0161-813X(03)00043-3. [DOI] [PubMed] [Google Scholar]
  • 18.Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced alodynia in the rat. Pain. 2001;93:69–76. doi: 10.1016/S0304-3959(01)00294-9. [DOI] [PubMed] [Google Scholar]
  • 19.Lynch JJ, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain. 2004;110:56–63. doi: 10.1016/j.pain.2004.03.010. [DOI] [PubMed] [Google Scholar]
  • 20.Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol. 2006;201:507–514. doi: 10.1016/j.expneurol.2006.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther. 1996;279:410–415. [PubMed] [Google Scholar]
  • 22.Bordet T, Buisson B, Michaud M, et al. Specific antinociceptive activity of cholest-4-en-3-one, Oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J Pharmacol Exp Ther. 2008;326:623–632. doi: 10.1124/jpet.108.139410. [DOI] [PubMed] [Google Scholar]
  • 23.Contreras PC, Vaught JL, Gruner JA, et al. Insulin-like growth factor-1 prevents development of a vincristine neuropathy in mice. Brain Res. 1997;774:20–26. doi: 10.1016/S0006-8993(97)81682-4. [DOI] [PubMed] [Google Scholar]
  • 24.Kamei J, Tamura N, Saitoh A. Possible involvement of the spinal nitric oxid/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 2005;117:112–120. doi: 10.1016/j.pain.2005.05.026. [DOI] [PubMed] [Google Scholar]
  • 25.Kiguchi N, Maeda T, Kobayashi Y, Kondo T, Ozaki M, Kishioka S. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. Europ J Pharmacol. 2008;592:87–92. doi: 10.1016/j.ejphar.2008.07.008. [DOI] [PubMed] [Google Scholar]
  • 26.Gauchan P, Andoh T, Ikeda K, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel subunit. Biol Pharm Bull. 2009;32:732–734. doi: 10.1248/bpb.32.732. [DOI] [PubMed] [Google Scholar]
  • 27.Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of Taxol. Exp Neurol. 1995;133:64–72. doi: 10.1006/exnr.1995.1008. [DOI] [PubMed] [Google Scholar]
  • 28.Cavaletti G, Cavaletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of short-term intravenous administration of paclitaxel in the rat. Neurotoxicol. 1997;18:137–145. [PubMed] [Google Scholar]
  • 29.Campana WM, Eskeland N, Calcutt NA, Misasi R, Myers RR, O’Brien JS. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicol. 1998;19:237–244. [PubMed] [Google Scholar]
  • 30.Cliffer KD, Siuciak JA, Carson SR, et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol. 1998;43:46–55. doi: 10.1002/ana.410430111. [DOI] [PubMed] [Google Scholar]
  • 31.Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–249. doi: 10.1016/S0006-8993(00)02910-3. [DOI] [PubMed] [Google Scholar]
  • 32.Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cε and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience. 2001;108:507–515. doi: 10.1016/S0306-4522(01)00425-0. [DOI] [PubMed] [Google Scholar]
  • 33.Polomano RC, Manes A, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001;94:293–304. doi: 10.1016/S0304-3959(01)00363-3. [DOI] [PubMed] [Google Scholar]
  • 34.Hatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245–257. doi: 10.1016/j.pain.2006.01.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol. 1991;29:87–90. doi: 10.1002/ana.410290115. [DOI] [PubMed] [Google Scholar]
  • 36.Wang MS, Davis AA, Culver DG, Glass JD. Wld mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol. 2002;52:442–447. doi: 10.1002/ana.10300. [DOI] [PubMed] [Google Scholar]
  • 37.Hidaka T, Shima T, Nagira K, et al. Herbal medicine Shakuyakukanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice. Europ J Pain. 2009;13:22–27. doi: 10.1016/j.ejpain.2008.03.003. [DOI] [PubMed] [Google Scholar]
  • 38.Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Europ J Cancer. 2005;41:1460–1466. doi: 10.1016/j.ejca.2005.04.006. [DOI] [PubMed] [Google Scholar]
  • 39.Roglio I, Bianchi R, Camozzi F, et al. Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Periph Nerv Syst. 2009;14:36–44. doi: 10.1111/j.1529-8027.2009.00204.x. [DOI] [PubMed] [Google Scholar]
  • 40.Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225–234. doi: 10.1016/j.pain.2006.09.016. [DOI] [PubMed] [Google Scholar]
  • 41.Ling B, Coudoré-Civiale MA, Balayssac D, Eschalier A, Coudore F, Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology. 2007;234:176–184. doi: 10.1016/j.tox.2007.02.013. [DOI] [PubMed] [Google Scholar]
  • 42.Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain. 2008;9:463–472. doi: 10.1016/j.jpain.2008.01.335. [DOI] [PubMed] [Google Scholar]
  • 43.Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain. 2009;10:534–541. doi: 10.1016/j.jpain.2008.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett. 2009;458:93–95. doi: 10.1016/j.neulet.2009.04.029. [DOI] [PubMed] [Google Scholar]
  • 45.Ta LE, Low PA, Windebauk AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain. 2009;5:9–9. doi: 10.1186/1744-8069-5-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tredici G, Tredici S, Fabbrica D, Minoia C, Cavaletti G. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol. 1998;36:31–40. doi: 10.1023/A:1005756023082. [DOI] [PubMed] [Google Scholar]
  • 47.Authier N, Fialip J, Eschalier A, Coudoré F. Assessment of allodynia and hyperalgesia after cisplatiu administration to rats. Neurosci Lett. 2000;291:73–76. doi: 10.1016/S0304-3940(00)01373-2. [DOI] [PubMed] [Google Scholar]
  • 48.Authier N, Gillet JP, Fialip J, Eschalier A, Coudoré F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol. 2003;182:12–20. doi: 10.1016/S0014-4886(03)00003-7. [DOI] [PubMed] [Google Scholar]
  • 49.Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatiu-induced chemoueuropathy. Brain Res. 2008;1230:91–98. doi: 10.1016/j.brainres.2008.07.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992;31:76–80. doi: 10.1002/ana.410310114. [DOI] [PubMed] [Google Scholar]
  • 51.Verdù E, Vilches JJ, Rodriguez FJ, Ceballos D, Valero A, Navarro X. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve. 1999;22:329–340. doi: 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  • 52.Aloe L, Manni L, Properzi F, De Santis S, Fiore M. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Autonom Neurosci. 2000;86:84–93. doi: 10.1016/S1566-0702(00)00247-2. [DOI] [PubMed] [Google Scholar]
  • 53.Marchand F, Alloui A, Pelissier T, et al. Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat. Brain Res. 2003;980:117–120. doi: 10.1016/S0006-8993(03)02946-9. [DOI] [PubMed] [Google Scholar]
  • 54.Flatters SJL, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150–161. doi: 10.1016/j.pain.2004.01.029. [DOI] [PubMed] [Google Scholar]
  • 55.Rahn E, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol. 2007;152:765–777. doi: 10.1038/sj.bjp.0707333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 2008;9:505–517. doi: 10.1111/j.1526-4637.2007.00301.x. [DOI] [PubMed] [Google Scholar]
  • 57.Thibault K, Bonnard E, Dubacq S, Fouruié-Zaluski MC, Roques B, Calvino B. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. Europ J Pharmacol. 2008;600:71–77. doi: 10.1016/j.ejphar.2008.10.004. [DOI] [PubMed] [Google Scholar]
  • 58.Gauchan P, Andoh T, Kato A, Sasaki A, Kuraishi Y. Effects of the prostaglandin E analog Limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. J Pharm Sci. 2009;109:469–472. doi: 10.1254/jphs.08325SC. [DOI] [PubMed] [Google Scholar]
  • 59.Pascual D, Goicoechea C, Suardiaz M, Martin MA. A cannabinoid agonist, WIN 55212-2 reduces neuropathic nociception induced by paclitaxel in rats. Pain. 2005;118:23–34. doi: 10.1016/j.pain.2005.07.008. [DOI] [PubMed] [Google Scholar]
  • 60.Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008;327:584–591. doi: 10.1124/jpet.108.141994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Naguib M, Diaz P, Xu JJ, et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Bri J Pharmacol. 2008;155:1104–1116. doi: 10.1038/bjp.2008.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Matsumoto M, Inoue M, Hald A, Xie W, Ueda H. Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther. 2006;318:735–740. doi: 10.1124/jpet.106.103614. [DOI] [PubMed] [Google Scholar]
  • 63.Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type 1 calcium channel subunit. Neuroscience. 2007;144:714–720. doi: 10.1016/j.neuroscience.2006.09.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Flatters SJL, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett. 2006;397:219–223. doi: 10.1016/j.neulet.2005.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Ling B, Coudoré F, Decalonne L, Eschalier A, Authier N. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacol. 2008;55:724–728. doi: 10.1016/j.neuropharm.2008.06.007. [DOI] [PubMed] [Google Scholar]
  • 66.Öztürk G, Erdogan E, Anlar Ö, Kösem M, Taspinar M. Effect of leukemia inhibitory factor in experimental cisplatin neuroathy in mice. Cytokine. 2005;25:31–34. doi: 10.1016/j.cyto.2004.09.006. [DOI] [PubMed] [Google Scholar]
  • 67.Sweitzer SM, Pahl JL, DeLeo JA. Propentofylline attenuate vincristine-induced peripheral neuropathy in the rat. Neurosci Lett. 2006;400:258–261. doi: 10.1016/j.neulet.2006.02.058. [DOI] [PubMed] [Google Scholar]
  • 68.Muthuraman A, Singh Jaggi A, Singh N, Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine-induced painful neuropathy in rats. Europ J Pharmacol. 2008;587:104–111. doi: 10.1016/j.ejphar.2008.03.042. [DOI] [PubMed] [Google Scholar]
  • 69.Bujalska M, Arazna M, Makulska-Nowak H, Gumulka SW. α1- and α2-adreuoreceptor antagonists in streptozocin- and vincristine-induced hyperalgesia. Pharmacol Rep. 2008;60:499–507. [PubMed] [Google Scholar]
  • 70.Bujalska M, Gumulka SW. Effect of cyclooxygenase and nitric oxide synthase inhibitors on vincristine induced hyperalgesia in rats. Pharmacol Rep. 2008;60:735–741. [PubMed] [Google Scholar]
  • 71.Cata JP, Weng HR, Dougherty PM. Cyclooxygenase inhibitors and thalidomide ameliorate vincristine-induced hyperalgesia in rats. Cancer Chemother Pharmacol. 2004;54:391–397. doi: 10.1007/s00280-004-0809-y. [DOI] [PubMed] [Google Scholar]
  • 72.Callizot N, Andriambeloson E, Glass J, et al. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapy activity. Cancer Chemother Pharmacol. 2008;62:995–1007. doi: 10.1007/s00280-008-0689-7. [DOI] [PubMed] [Google Scholar]
  • 73.Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol. 2001;48:429–434. doi: 10.1007/s00280-001-0382-6. [DOI] [PubMed] [Google Scholar]
  • 74.Ledeboer AM, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root gangia in rats. Brain Behav Immun. 2007;21:686–698. doi: 10.1016/j.bbi.2006.10.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol. 1991;29:87–90. doi: 10.1002/ana.410290115. [DOI] [PubMed] [Google Scholar]
  • 76.Campana WM, Eskeland N, Calcutt NA, Misasi R, Myers RR, O’Brien JS. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicity. 1998;19:237–244. [PubMed] [Google Scholar]
  • 77.Jolivalt CG, Ramos KM, Herbetsson K, Esch FS, Calcutt NA. Therapeutic efficacy of prosaposin-derived peptide on different models of allodynia. Pain. 2006;121:14–21. doi: 10.1016/j.pain.2005.11.013. [DOI] [PubMed] [Google Scholar]
  • 78.Kawashiri T, Egashira N, Itoh T, et al. Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy. Eur J Cancer. 2009;45:154–163. doi: 10.1016/j.ejca.2008.10.004. [DOI] [PubMed] [Google Scholar]
  • 79.Chentanez V, Thanomsridejchai N, Duangmardphon N, et al. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai. 2009;92:50–57. [PubMed] [Google Scholar]
  • 80.Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res. 2005;25:2681–2687. [PubMed] [Google Scholar]
  • 81.Bianchi R, Brines M, Lauria G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res. 2006;12:2607–2612. doi: 10.1158/1078-0432.CCR-05-2177. [DOI] [PubMed] [Google Scholar]
  • 82.Bianchi R, Gilardini A, Rodriguez-Menendez V, et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Europ J Cancer. 2007;43:710–717. doi: 10.1016/j.ejca.2006.09.028. [DOI] [PubMed] [Google Scholar]
  • 83.Apfel SC, Arezzo JC, Liptson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992;31:76–80. doi: 10.1002/ana.410310114. [DOI] [PubMed] [Google Scholar]
  • 84.Vera G, Chiarlone A, Cabezos PA, Pascual D, Martin MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Lif Sci. 2007;81:468–479. doi: 10.1016/j.lfs.2007.06.012. [DOI] [PubMed] [Google Scholar]
  • 85.Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology. 2009;149:455–460. doi: 10.1210/en.2007-0828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Mogil JS, Crager SE. What should we be measuring in behavioral studies of chronic pain in animals? Pain. 2004;112:12–15. doi: 10.1016/j.pain.2004.09.028. [DOI] [PubMed] [Google Scholar]
  • 87.Steinberg M. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther. 2008;30:1590–1617. doi: 10.1016/j.clinthera.2008.09.015. [DOI] [PubMed] [Google Scholar]
  • 88.Pacharinsak C, Beitz A. Animal models of cancer pain. Comp Med. 2008;58:220–233. [PMC free article] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES